TRVN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders...

Stats
Šios dienos apimtis	45 376.00
Vidutinė apimtis	208 769
Rinkos kapitalizacija	5.93M
EPS	$0 ( 2024-04-04 )
Kita pelno data	( $-0.470 ) 2024-06-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0600
ATR14	$0.00900 (2.22%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-14	Drake Patricia M.	Buy	25 000	Common Stock
2023-12-14	Drake Patricia M.	Sell	1 835	Common Stock
2023-12-14	Drake Patricia M.	Buy	50 000	Common Stock
2023-12-14	Bourdow Carrie L.	Buy	100 000	Common Stock
2023-12-14	Bourdow Carrie L.	Sell	7 123	Common Stock

INSIDER POWER
92.78
Last 98 transactions
Buy: 7 332 092 \| Sell: 537 308

Tūris Koreliacija

Ilgas: -0.23 (neutral)

Trumpas: -0.93 (very strong negative)

Signal:(52.924) Neutral

Trevena Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
AVO	0.962
SWVL	0.94
RPID	0.938
QLGN	0.938
ARQQ	0.936
XFOR	0.934
LYRA	0.932
ASPS	0.932
ALZN	0.93
GOSS	0.929

10 Labiausiai neigiamai susiję koreliacijos
STAY	-0.95
ACAB	-0.943
GLLI	-0.942
FNVT	-0.939
HZNP	-0.937
CIIG	-0.936
AVAC	-0.933
NWFL	-0.931
TIPT	-0.929
LRFC	-0.929

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Trevena Inc Koreliacija - Valiuta/Žaliavos

-0.54
( weak negative )

-0.51
( weak negative )

0.00
( neutral )

0.15
( neutral )

Trevena Inc Finansinės ataskaitos

Annual	2022
Pajamos:	$-418 000
Bruto pelnas:	$-3.44M (822.01 %)
EPS:	$-7.59

FY	2022
Pajamos:	$-418 000
Bruto pelnas:	$-3.44M (822.01 %)
EPS:	$-7.59

FY	2021
Pajamos:	$567.00
Bruto pelnas:	$-387.00 (-68.25 %)
EPS:	$-0.0101

FY	2020
Pajamos:	$3.07M
Bruto pelnas:	$2.89M (94.07 %)
EPS:	$-5.75

Financial Reports:

No articles found.

Trevena Inc

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.